Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)

乳腺癌幸存者的超长期神经认知结果（ProbC2）

基本信息

批准号：
10558447
负责人：
Oxana G Palesh
金额：
$ 31.52万
依托单位：
VIRGINIA COMMONWEALTH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10558447
关键词：
Acceleration Address Aftercare Age Aging Brain Breast Cancer survivor Chemotherapy-Oncologic Procedure Cognition Cognitive Cognitive deficits Control Groups Data Decision Making Disease remission Elderly Funding Mechanisms Impaired cognition Impairment Incidence Knowledge Literature Longitudinal Studies Malignant Neoplasms Measures Methods Morbidity - disease rate Nature Neurobiology Neurocognitive Neuropsychological Tests Neuropsychology Outcome Participant Patients Performance Phenotype Physiological Processes Process Prospective Studies Quality of life Reporting Research Structure Survivors Time Woman Work aging brain cancer-related cognitive impairment chemobrain chemotherapy clinically significant cognitive change cognitive function cognitive neuroscience cognitive testing cohort comparison control connectome disability experience follow-up high risk longitudinal, prospective study malignant breast neoplasm mortality neural neural circuit neuroimaging neuromechanism resilience standardize measure

项目摘要

PROJECT SUMMARY/ABSTRACT Chemotherapy-related cognitive impairment (CRCI) is associated with reduced quality of life and survival making it a significant problem that remains understudied. Research by our group and others has demonstrated that CRCI is associated with altered brain structure and function from pretreatment to post treatment. There is significant overlap between chemotherapy actions and physiologic processes involved in aging. Neurocognitive have been found in patients up to 20+ years post- treatment and work by our group and others suggests an accelerated brain aging phenotype in breast cancer survivors treated with chemotherapy. We have also observed that patients may demonstrate unique trajectories of cognitive impairment that require further study. Existing prospective, longitudinal studies of cancer and cognition, including our own, have been limited to relatively short-term post- treatment follow-ups (e.g. 6-12 months). To begin addressing these limitations, we aim to extend our current prospective study (CA172145), which longitudinally examines cognitive function and brain structure/function pre-surgery, 1-month post chemotherapy, and 1-year post chemotherapy. We will continue to assess cohorts of women treated with chemotherapy, chemotherapy naïve patients, and healthy controls at yearly intervals for 5 additional years (up to 10 years). Using non-invasive neuroimaging methods, we will advance our original aims from the initial project to measure very long- term neurobiologic outcomes with an emphasis on the assessment of neural connectivity rather than specific regional changes (Aim 1). We will also examine very long-term cognitive outcomes as measured by standardized neuropsychological testing (Aim 2). Finally, we will explore different trajectories or subtypes of impairment and their neural phenotypes (Aim 3). The proposed project will significantly advance the understanding of chemotherapy-related cognitive impairments by extending our knowledge on very long-term neurobiological outcomes along with the different subtypes of cognitive impairments and associated neural profiles following breast cancer chemotherapy.

项目概要/摘要化疗相关认知障碍（CRCI）与生活质量下降和生存使其成为我们小组和其他人仍在研究的一个重要问题。已证明 CRCI 与预处理的大脑结构和功能相关化疗作用和治疗后的生理作用之间存在显着重叠。在20多年后的患者中发现了与衰老有关的神经认知过程。我们小组和其他人的治疗和工作表明乳房中大脑加速老化的表型我们还观察到接受化疗的癌症幸存者可能会表现出这种情况。认知障碍的独特轨迹需要进一步研究。对癌症和认知的研究，包括我们自己的研究，都仅限于相对短期的术后研究。治疗随访（例如 6-12 个月）为了开始解决这些限制，我们的目标是延长治疗随访时间。当前的前瞻性研究（CA172145），纵向检查认知功能和大脑手术前、化疗后 1 个月和化疗后 1 年的结构/功能。继续评估接受化疗的女性、未接受化疗的患者以及每年进行一次健康对照，持续 5 年（最多 10 年）。神经影像方法，我们将把最初的目标从最初的项目推进到测量很长的时间- 术语神经生物学结果强调神经连接的评估而不是我们还将研究非常长期的认知结果：最后，我们将探索不同的方法。损伤的轨迹或亚型及其神经表型（目标 3）。通过扩展显着增进对化疗相关认知障碍的理解我们对长期神经生物学结果以及不同亚型的了解乳腺癌化疗后的认知障碍和相关神经特征。